Brand name: Arcapta Neohaler
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.
More information on indacaterol maleate (Arcapta Neohaler)
- Letter to HHS Regarding OHRP Failure to Investigate Unethical Placebo-Controlled Trials of Indacaterol Maleate (Arcapta Neohaler), April 28, 2011
- Letter to FDA on Indacaterol Maleate (Arcapta Neohaler), March 16, 2011
- Letter to OHRP on Unethical Trials of Indacaterol Maleate (Arcapta Neohaler), March 16, 2011
- Testimony on Indacaterol Maleate (Arcapta Neohaler), March 8, 2011